The 5 most recent market catalysts affecting $BYSI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 14, 2026
Corporate Catalyst
Neutral
Impact 92
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring's Q3 2026 filing reveals a net loss of $2.1 million, an increase from $1.6 million in the prior year, and a dangerously low cash balance of $0.6 million. This financia…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 75
BeyondSpring shares are trading lower. The company announced the FDA has granted Fast Track designation to Plinabulin and docetaxel for advanced non-small cell lung cancer.
The Fast Track designation for Plinabulin and docetaxel is generally a positive development for a biotechnology company, as it can expedite the drug's review process and potential …
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 85
BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment
The FDA Fast Track designation for Plinabulin plus Docetaxel in lung cancer is a major positive for BeyondSpring, indicating accelerated review and potential earlier market entry f…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (BYSI) announced a significant reduction in its quarterly losses, with EPS improving from $(0.04) to $(0.02) year-over-year. This 50% improvement suggests that the com…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
The FDA Orphan Drug Designation for ST-01156 is a significant positive catalyst for BeyondSpring. This designation grants special incentives, including tax credits, fee waivers, an…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.